Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HEPA running in pre...ready for 73c
$HEPA: I been tellin ya forever about NASH
Maybe you were paying attention…. Maybe whining when
it hit fresh new lows last year.
But all I kept saying is look at MDGL Madrigal…. Same SPACE.
You can’t count HEPION out…. And yes, I’m doing mighty fine.
NASH is where it’s at right now, bigggg time.
GO $HEPA
Hopefully you held some lotto tickets for this ride. I just May get lucky and get out someday with my shirt on.
$HEPA: What do you mean is the pump over ??
Is the pump over on MDGL ????
DO you think this is an APE stock ???
They just received $3.5Milly in NonDilutive Financing today..... does that mean there
is a pump here ??
If so, you need to do more work to figure things out.
But yes, it is nice to buy the botom of the chart. NASH isn't going anywhere.
Lemme know when they've resolved NASH and these stocks won't mean anything to
anyone out there
GO $HEPA
Must be nice to buy the bottom. Damn your good. Is the pump over?
$HEPA: Receives $3.2Milly in NonDilutive FUNDING today
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
NEWS PROVIDED BY
GlobeNewswire
January 09, 2023, 13:00 GMT
SHARE THIS ARTICLE
Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus $0.3 Million from Alberta Innovation Employment Grant
/EIN News/ -- EDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced the receipt of $2.9 million in net proceeds from the sale of tax benefits pursuant to the Company’s participation in the New Jersey Economic Development Authority (“NJEDA”) NOL program under the New Jersey Economic Recovery Act of 2020, and receipt of a C$416,415 (US$309,000) Alberta Innovation Employment Grant.
NJEDA’s NOL program enables qualified, New Jersey-based technology or biotechnology companies to sell net operating losses to unrelated profitable corporations. This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development (“R&D”) or other allowable expenditures.
Alberta’s Innovation Employment Grant program encourages economic growth by supporting small and medium-sized businesses that invest in R&D with a grant worth up to 20% of qualifying expenditures. The program promotes investment and diversification by rewarding all R&D spending in Alberta, Canada, regardless of the industry.
"We appreciate the support of both the State of New Jersey and the Province of Alberta to support innovation within their respective business communities," said Robert Foster, PharmD, PhD, Hepion’s CEO. "This non-dilutive funding adds to the approximate $59.1 million in cash we had as of the end of Q3-2022, further strengthening the Company’s balance sheet as we continue to advance rencofilstat, our lead oral drug candidate for the treatment of NASH and HCC.”
About Hepion Pharmaceuticals
The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in the cyclophilin inhibition therapeutic space.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
GO $HEPA
$HEPA: I'm up Double already...........
So, can't speak for your position..... gotta get those GOOD ENtries where you can.
Doing not tooooooooooooooo bad myself.
Here and in other plays as well this year.
GO $HEPA
I own enough, but unfortunately my costs are a bit higher. Been in here too long. Hate to throw good money after bad especially with a RS possible at any time.
$HEPA: Remember when I said "STUPID CHEAP @ $0.33"
That was no JOKE....... now $0.54
Now you KNOW !!!!!!!!!!!!!!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170756736
JPMorgan Healthcare Conference THIS week as well.
GO $HEPA
$HEPA: Now over $0.50....... and JPMorgan Conference.
Hopefully you were buying while you were complaining.
Its nothing but NASH NASH NASHHHHhhhhhhhhhhhhhhhhh these days.
I told ya.
And HEPA is still undervalued by at least $10/sh
JUst look over at $MDGL and you'll get it.
GO $HEPA
$HEPA: Now 0.47........... Lagging all the NASH players
YOU were all told........... I told you.
MDGL over $300 share right now ??
CMOOOOOOOoonnnnnnnnnnnnnnnnnnn............. this puppy has lots of UPSIDE room to it
GO $HEPA
ALGS is much better NASH stock.
Easily moves to $3 by February.
Run starts today.
$HEPA: Trading below cash on HAND..... $58Milly Cash
And MarketCap is only at $23Milly
This is sooooooooo undervalued.
And thats outside of the fact that this is a NASH related BIOtech which have been SUPER HOT runners today
GO $HEPA
$HEPA: Sleeper play...... you just saw JSPR and LHDX roll
Here at $0.30............ this doesn't get any better
Tight stops to limit losses if you get the heebie jeebies
GO $HEPA
$HEPA: ANother NASH player rolling today......... ChemoMAB
Its only a matter of time before Hepion fires off.
JP Morgan Health Conferecne is coming up in a few weeks............ maybe by then.
$0.30 here looks like a steal
GO $HEPA
$HEPA: NASH NASH NASH NASH NASHHHHHhhhhhhhhhhhhhhhhh
One look at $MDGL and you will BELIEVE !!!!!!!!!!!!!
2023 is the year for HEPION !!!!!!!!!
GO $HEPA
$HEPA: Stop focusing your time here...........
And make up ground elsewhere then.
I just called out $TGTX.............. and it just got FDA approved.
$HEPA isn't the only game in town............ unless you put 100% of your eggs in this
one basket which is a unintelligent move.
While we wait our turn, MDGL and TGTX and other bios are flying
HEPA will happen..... we are a dIRECT competitor to MDGL
GO $HEPA
I hope so but right now I’m down 70% on my original investment and we continue to make daily lows.
$HEPA: You are wrong................
If you don't like it, move on
https://hepionpharma.com/wp-content/uploads/2022/12/Hepion-Corporate-Slide-Deck-December-2022.pdf
GO $HEPA
This company is a scam. 1/20 RS on its way. We’re all screwed here.
$HEPA: Same sppace as $MDGL.... should be shooting up soon
I can see HEPA going over $3 share...... very low here at $0.29 now
You just saw what happened to $MDGL this month.
Can't keep $HEPA outta the same picture..... its a Direct Competitor to $MDGL
GO $HEPA
*******************************************************************************************
https://finance.yahoo.com/news/propulsion-nonalcoholic-steatohepatitis-pipeline-novel-153000073.html
Propulsion of Nonalcoholic Steatohepatitis Pipeline as Novel and Extensive 150+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
December 12, 2022·10 min read
The prevalence of nonalcoholic steatohepatitis has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Nonalcoholic Steatohepatitis and the growing research and development activities drive the market. The Companies developing the potential therapies in the last stage of development include Madrigal Pharmaceuticals, Inventiva, Boehringer Ingelheim, and several others.
LAS VEGAS, Dec. 12, 2022 /PRNewswire/ -- DelveInsight's 'Nonalcoholic Steatohepatitis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline nonalcoholic steatohepatitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the nonalcoholic steatohepatitis pipeline domain.
DelveInsight_Logo
DelveInsight_Logo
Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report
DelveInsight's nonalcoholic steatohepatitis pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for nonalcoholic steatohepatitis treatment.
Key nonalcoholic steatohepatitis companies such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others are evaluating nonalcoholic steatohepatitis drugs to improve the treatment landscape.
Promising nonalcoholic steatohepatitis pipeline therapies in various stages of development include TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), PXL065, ALS-L1023, PF-06865571 + PF-05221304, PF-06835919, PF-06865571, ORMD-0801, Norucholic acid, NNC0194-0499, MN-001, MK-3655, MET642, MET409, LPCN 1144, LIK066, Leronlimab, ALN-HSD, MT-3995, CM101, Leu-Mit-Sil (NS-0200), IN-A010, Efruxifermin (EFX), Efinopegdutide, EDP-305, JKB-122, CS0159 (Linafexor), CRV431, Chiglitazar sodium, BOS-580, BMS-986263, HEC96719, GSK4532990, FM101, Firsocostat, EPY001a, Emricasan, BMS-986036, BIO89-100, BI 456906, BFKB8488A, AXA1125, ASC 41, GS-9674 (Cilofexor), ZSP1601, and others.
In November 2022, Sagimet Biosciences announced positive interim data from its Phase IIb clinical trial (FASCINATE-2) with denifanstat, a fatty acid synthase (FASN) inhibitor, in non-alcoholic steatohepatitis patients. Data showed statistically significant improvements across key markers of NASH, reinforcing results observed in earlier studies, including statistically significant reductions in markers of liver fat, inflammation, and fibrosis. There were no treatment-related serious adverse events, with the majority of adverse events mild to moderate in nature (Grade 1 and 2). Additional interim data are expected in early 2023.
In November 2022, Inventiva announced that the United States Patent and Trademark Office granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage. This patent will expire on November 8, 2039. This patent further expands the intellectual property protection of lanifibranor in the United States for use in patients with cirrhotic NASH.
In October 2022, Galectin Therapeutics, Inc. reported the positive outcome of its second data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase IIb/III study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The objective of this second independent DSMB was further to review the emerging tolerance and safety profiles of belapectin. Based on its deliberation, the DSMB concluded that NAVIGATE could continue as designed, without modifications.
In September 2022, Inventiva and Chia Tai-Tianqing Pharmaceutical Group entered into a licensing and collaboration agreement to develop and commercialize lanifibranor, if approved, for the treatment of nonalcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.
In June 2022, Poxel SA announced that the U.S. Patent and Trademark Office (PTO) has issued to Poxel US Patent No. 11319313, which represents a new patent for PXL065, a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which is being investigated in Phase II stage of clinical trial evaluation for the treatment of Nonalcoholic steatohepatitis (NASH).
In May 2022, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
In May 2022, Hepion Pharmaceuticals, Inc. announced that it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate the HepQuant 'SHUNT' test into a dedicated Phase IIb clinical trial in presumed NASH F3 subjects.
In February 2022, the US Food and Drug Administration (FDA) granted a Fast-Track Designation to Axcella Therapeutics' AXA1125 to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis.
In January 2022, LISCure Biosciences announced that it had executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure Biosciences Inc. has executed a research collaboration agreement with US based-Mayo Clinic for new drug development for rare liver diseases.
Request a sample and discover the nash drugs in development 2022 @Nonalcoholic Steatohepatitis Pipeline 2022 Report
The nonalcoholic steatohepatitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage nonalcoholic steatohepatitis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the nonalcoholic steatohepatitis clinical trial landscape.
Nonalcoholic Steatohepatitis Overview
Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by fat buildup. It is one of several conditions known as nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease is classified into two types: isolated fatty liver, in which only fat accumulates, and nonalcoholic steatohepatitis, in which fat, inflammation, and liver cell damage occur.
NASH does not usually cause symptoms. Most people with NASH feel fine and are unaware that they have it. As NASH progresses and liver damage worsens, a patient may experience fatigue, weight loss, general weakness, and acne in the upper right part of the belly. Screening for nonalcoholic fatty liver disease in the general population is not advised. It is usually considered after discovering unexplained liver enzyme levels, or imaging reveals hepatic steatosis. A patient's medical history, a physical exam, and tests for nonalcoholic steatohepatitis are used by doctors.
Want to discover how the Nash treatment pipeline will look like? Request for sample @NASH Drug Pipeline 2022
A snapshot of the Nonalcoholic Steatohepatitis Pipeline Drugs mentioned in the report:
Drugs
Company
Phase
MoA
RoA
Resmetirom
Madrigal Pharmaceuticals
Phase III
Thyroid hormone receptor beta agonists
Oral
Lanifibranor
Inventiva
Phase III
Peroxisome proliferator-activated receptor alpha agonist
Oral
BI 456906
Boehringer Ingelheim
Phase II
Glucagon like peptide 1 receptor agonist
Subcutaneous
ORMD-0801
Oramed Pharmaceuticals
Phase II
Ornithine decarboxylase stimulant
Oral
EYP001
ENYO Pharma
Phase II
Farnesoid X-activated receptor agonist
Oral
TERN-501|TERN-101
Terns Pharmaceuticals
Phase II
Thyroid hormone receptor beta agonist
Oral
AZD 2693
AstraZeneca
Phase I
Adiponutrin inhibitor
Subcutaneous
AMG 609
Amgen
Phase I
RNA interference
Subcutaneous
LY-3849891
Eli Lilly and Company
Phase I
RNA interference
Subcutaneous
GMA-107
Gmax Biopharm
Preclinical
NA
Parenteral
VK-1430
Viking Therapeutics
Preclinical
Diacylglycerol O acyltransferase inhibitor
NA
Want to know how nash dash the pipeline race is for new agents? Download the sample page @NASH Clinical Trials
Nonalcoholic Steatohepatitis Therapeutics Assessment
The nonalcoholic steatohepatitis pipeline report proffers an integral view of nonalcoholic steatohepatitis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Nonalcoholic Steatohepatitis Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intravenous, Parenteral, Oral, Subcutaneous
Therapeutics Assessment By Molecule Type: Antibody, Biologic, Cell therapy, Peptide, Protein, Small molecule
Therapeutics Assessment By Mechanism of Action: Adiponutrin inhibitor, Diacylglycerol O acyltransferase inhibitor, Adiponutrin modulator, RNA interference, Glucagon like peptide 1 receptor agonist, Ornithine decarboxylase stimulant, Farnesoid X-activated receptor agonist, Thyroid hormone receptor beta agonist, Mitochondrial membrane transport protein modulator, Thyroid hormone receptor beta agonists, Peroxisome proliferator-activated receptor alpha agonist
Key Nonalcoholic Steatohepatitis Companies:Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others.
Key Nonalcoholic Steatohepatitis Pipeline Therapies: TERN-101, SNP-610, LJN452(tropifexor + licogliflozin), PXL065, ALS-L1023, PF-06865571 + PF-05221304, PF-06835919, PF-06865571, ORMD-0801, Norucholic acid, NNC0194-0499, MN-001, MK-3655, MET642, MET409, LPCN 1144, LIK066, Leronlimab, ALN-HSD, MT-3995, CM101, Leu-Mit-Sil (NS-0200), IN-A010, Efruxifermin (EFX), Efinopegdutide, EDP-305, JKB-122, CS0159 (Linafexor), CRV431, Chiglitazar sodium, BOS-580, BMS-986263, HEC96719, GSK4532990, FM101, Firsocostat, EPY001a, Emricasan, BMS-986036, BIO89-100, BI 456906, BFKB8488A, AXA1125, ASC 41, GS-9674 (Cilofexor), ZSP1601, and others.
Dive deep into rich insights for nonalcoholic steatohepatitis research; visit @NASH Treatment Pipeline
Table of Contents
1.
Nonalcoholic Steatohepatitis Pipeline Report Introduction
2.
Nonalcoholic Steatohepatitis Pipeline Report Executive Summary
3.
Nonalcoholic Steatohepatitis Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Nonalcoholic Steatohepatitis Clinical Trial Therapeutics
6.
Nonalcoholic Steatohepatitis Pipeline: Late Stage Products (Pre-registration)
7.
Nonalcoholic Steatohepatitis Pipeline: Late Stage Products (Phase III)
7.1
Resmetirom: Madrigal Pharmaceuticals
8.
Nonalcoholic Steatohepatitis Pipeline: Mid Stage Products (Phase II)
8.1
BI 456906: Boehringer Ingelheim
9.
Nonalcoholic Steatohepatitis Pipeline: Early Stage Products (Phase I)
9.1
AZD 2693: AstraZeneca
10.
Nonalcoholic Steatohepatitis Pipeline Therapeutics Assessment
11.
Inactive Products in the Nonalcoholic Steatohepatitis Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products in the Nonalcoholic Steatohepatitis Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the most promising nash drugs, reach out @NASH Medication Pipeline
Related Reports
Nonalcoholic Steatohepatitis Epidemiology
Nonalcoholic Steatohepatitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted nonalcoholic steatohepatitis epidemiology in the 7MM.
Nonalcoholic Steatohepatitis Market
Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, Cirius Therapeutics, among others.
Non-Alcoholic Fatty Liver Disease Market
Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.
Non-Alcoholic Fatty Liver Disease Pipeline
Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced non-alcoholic fatty liver disease companies, including AstraZeneca, Novartis, Pfizer, Roche, among others.
Non-Alcoholic Fatty Liver Disease Epidemiology
Non-Alcoholic Fatty Liver Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted non-alcoholic fatty liver disease epidemiology in the 7MM.
Other Trending Reports
Alcohol Use Disorder Market | Liver Cancer Market | Alcoholic Hepatitis - Market | Acute Liver Failure - Market | Liver Angiosarcoma - Market | Liver Cirrhosis - Market | Chronic Liver Disease - Market | Advanced Liver Cancer - Market | Acute On Chronic Liver Failure (ACLF) Market
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
$HEPA: MDGL moves 60 to $300 this week...... NASH-news
We need to be over $1 MINIMUM already right now.
HEPA has beeen in NASH foreverzzzzzzzzzzz
GO $HEPA
Wrong. Totally different drug with different mechanism of action.
What makes MDGL so exciting? Their main drug, resmetirom, is a thyroid hormone receptor (THR)-ß selective agonist.
The only companies who have THR drugs are VKTX, TERN, and ALGS.
TERN is an amazing company where insiders bought lots of shares recently.
ALGS is the cheapest of the 3 companies trading at $0.95.
$HEPA: With MDGL boosting on NASH news.................
HEPA is in the same space.......... surrpised this hasn't launched off yet.
Even $VKTX in the same space is following $MDGL, even though not as much, but still moving up.
HEPA should at least get over $10/sh.... stupid cheap here at 0.33
https://hepionpharma.com/news/hepion-pharmaceuticals-announces-early-completion-of-enrollment-in-phase-2-altitude-nash-liver-function-trial/
https://hepionpharma.com/wp-content/uploads/2022/11/Hepion-Corporate-Slide-Deck-November-2022.pdf
NASH stocks are HOT HOT HOTTTTTTTTTTTTTTTTT
GO $HEPA
Dear Stockholder:
We are pleased to invite you to attend the Special Meeting of stockholders (the “Special Meeting”) of Hepion Pharmaceuticals, Inc. (“Hepion” or the “Company”), which will be held on December 15, 2022 at 9:00 a.m. local time at our offices, located at 399 Thornall Street, First Floor, Edison, NJ 08837, for the following purposes:
1. To grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-twenty (1-for-20) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders; and
2. To transact such other matters as may properly come before the Special Meeting and any adjournment or postponement thereof.
Our board of directors has fixed the close of business on November 8, 2022 as the record date for a determination of stockholders entitled to notice of, and to vote at, the Special Meeting or any adjournment or postponement thereof.
https://ih.advfn.com/stock-market/NASDAQ/hepion-pharmaceuticals-HEPA/stock-news/89607816/proxy-statement-definitive-def-14a
Statement of the year
Totally SCREWED the chart.
Scumbags will do anything for the RS. Looks like they will finally get it. This company is full of crooks.
Keep an eye on this puppy. Just a BooDog hunch.
HEPA daily
https://finance.yahoo.com/news/upcoming-presentation-joint-meeting-isbra-120000973.html
P2b kick off.
https://ih.advfn.com/p.php?pid=nmona&article=88954854
Over 1 year is that considered soon enough
I hope this dude didnt drown LMAO
Alot of people have dumped. The thing is it hasnt almost pumped like a pharma should in the last 1.5 years
You dump and run? This really turned into a terrible story.
That worked out well. Crime family hard at work.
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
Source: GlobeNewswire Inc.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of HCC.
HCC is the most common form of liver cancer, accounting for 85-90% of all cases. NASH, viral hepatitis infection, and alcohol consumption all are major causes of HCC. Worldwide, it is estimated that over 800,000 people died from liver cancer in 2020, second only to lung cancer among all cancer-related deaths.1 The high mortality is largely due to the fact that only around half of all people who develop HCC (in developed countries) receive the diagnosis early enough to have an opportunity for therapeutic intervention. Additionally, recurrence rates are high, and effective treatment options remain limited.
“Orphan Drug Designation for rencofilstat in HCC represents a significant milestone for Hepion and its recognition by the FDA of the potential for rencofilstat to address a significant unmet medical need for patients suffering from this aggressive cancer,” said Robert Foster, PharmD, PhD, Hepion’s CEO. “In addition to two Phase 2 studies in patients with NASH, we remain on track to initiate patient enrollment in a Phase 2a study of rencofilstat in HCC in the third quarter of 2022.”
The FDA's Orphan Drug Designation program provides orphan status to drugs or biologics intended for the prevention, diagnosis, or treatment of diseases that affect fewer than 200,000 people in the United States. Sponsors of medicines that are granted Orphan Drug Designation are entitled to certain incentives, including tax credits for qualified clinical trials, prescription drug user-fee exemptions, and potential seven-year marketing exclusivity upon FDA approval.
Who releases news on a holiday? Only a bunch of thieves and idiots. Vote NO to all proposals.
Discount. lol most of the market is printing discounts though. Crazy. But I'll take this one. Manipulation at its finest. And certainly helping it is the plan to add to the authorized. And when they do their next offering just maybe this'll be well over $1.
Short squeeze coming as well. Filings next week shall paint an interesting picture.
Just like his money long gone
I wonder where the account holder for “fress” went. Must have multiple accounts. One of his messages is pinned on the board and its the only one. Apparently in hawaii since july 2021 for a couple more weeks of vacation. Not a good image for this board. Poor moderation. Remove it. But then again ihub is for geezers lmao
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2150
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |